Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
CT-guided cryoablation proves its staying power for early kidney cancer. A large European registry study found that patients with early-stage renal cell carcinoma (RCC) who underwent CT-guided percutaneous cryoablation had a 5-year local recurrence-free survival rate of 96.1%. With just a 1-day median hospital stay and minimal major complications, the minimally invasive approach is making a strong case as a surgery-sparing option.
CT-guided percutaneous cryoablation is proving to be a durable, low-burden treatment for patients with early-stage renal cell carcinoma (RCC) who aren't ideal surgical candidates. Presented at IKCS: North America 2026, findings from the European Registry for Renal Cryoablation (EuRECA) showed impressive long-term outcomes across 757 patients treated between 2014 and 2020, with a median follow-up of 5 years.
The procedure achieved primary technique efficacy in 97.9% of patients, and only 28 went on to develop local disease recurrence. Metastatic progression was rare, and just 4 patients died from RCC over the study period. For those who needed a repeat procedure, secondary technique efficacy still came in at 87.5%.
By the Numbers:
Why it matters: For patients with cT1a RCC who can't or shouldn't undergo surgery, cryoablation offers a guideline-consistent, kidney-sparing alternative with outcomes that rival surgical benchmarks — and a recovery time that's hard to beat.